CN113166195A - 在正在治疗高胆固醇相关疾病的患者中降低糖尿病风险的方法 - Google Patents

在正在治疗高胆固醇相关疾病的患者中降低糖尿病风险的方法 Download PDF

Info

Publication number
CN113166195A
CN113166195A CN201980067823.7A CN201980067823A CN113166195A CN 113166195 A CN113166195 A CN 113166195A CN 201980067823 A CN201980067823 A CN 201980067823A CN 113166195 A CN113166195 A CN 113166195A
Authority
CN
China
Prior art keywords
subject
diabetes
ezetimibe
fixed dose
aspects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980067823.7A
Other languages
English (en)
Chinese (zh)
Inventor
N.D.拉尔瓦尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esperion Therapeutics Inc
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69591419&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN113166195(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of CN113166195A publication Critical patent/CN113166195A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980067823.7A 2018-08-24 2019-08-26 在正在治疗高胆固醇相关疾病的患者中降低糖尿病风险的方法 Pending CN113166195A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862722766P 2018-08-24 2018-08-24
US62/722,766 2018-08-24
US201862751404P 2018-10-26 2018-10-26
US62/751,404 2018-10-26
PCT/US2019/048184 WO2020041799A1 (en) 2018-08-24 2019-08-26 Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses

Publications (1)

Publication Number Publication Date
CN113166195A true CN113166195A (zh) 2021-07-23

Family

ID=69591419

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980067823.7A Pending CN113166195A (zh) 2018-08-24 2019-08-26 在正在治疗高胆固醇相关疾病的患者中降低糖尿病风险的方法

Country Status (15)

Country Link
US (1) US20210322376A1 (https=)
EP (1) EP3841105A4 (https=)
JP (2) JP2021534208A (https=)
KR (1) KR20210079275A (https=)
CN (1) CN113166195A (https=)
AU (1) AU2019325705A1 (https=)
BR (1) BR112021003265A2 (https=)
CA (1) CA3110346A1 (https=)
CL (1) CL2021000444A1 (https=)
CO (1) CO2021003726A2 (https=)
IL (1) IL281016A (https=)
MX (1) MX2021002090A (https=)
PH (1) PH12021550656A1 (https=)
SG (1) SG11202101717WA (https=)
WO (1) WO2020041799A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3267989A4 (en) 2015-03-13 2018-11-07 Esperion Therapeutics, Inc. Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
US20210322375A1 (en) * 2018-08-27 2021-10-21 Esperion Therapeutics, Inc. Combination drug formulations for treating patients with cardiovascular disease and associated conditions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112166A2 (en) * 2007-03-09 2008-09-18 Indigene Pharmaceuticals Inc. Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
CN103239449A (zh) * 2012-12-26 2013-08-14 辽宁亿灵科创生物医药科技有限公司 一种依折麦布、辛伐他汀和烟酸的复方制剂及其制备方法
CN103841992A (zh) * 2011-05-10 2014-06-04 安姆根有限公司 治疗或预防胆固醇相关疾病的方法
US20180078518A1 (en) * 2015-03-16 2018-03-22 Esperion Therapeutics, Inc. Fixed Dose Combinations and Formulations Comprising ETC1002 and One or More Statins and Methods of Treating or Reducing Cardiovascular Disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018148417A1 (en) * 2017-02-08 2018-08-16 Esperion Therapeutics, Inc. Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112166A2 (en) * 2007-03-09 2008-09-18 Indigene Pharmaceuticals Inc. Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
CN103841992A (zh) * 2011-05-10 2014-06-04 安姆根有限公司 治疗或预防胆固醇相关疾病的方法
CN103239449A (zh) * 2012-12-26 2013-08-14 辽宁亿灵科创生物医药科技有限公司 一种依折麦布、辛伐他汀和烟酸的复方制剂及其制备方法
US20180078518A1 (en) * 2015-03-16 2018-03-22 Esperion Therapeutics, Inc. Fixed Dose Combinations and Formulations Comprising ETC1002 and One or More Statins and Methods of Treating or Reducing Cardiovascular Disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHRISTIE M. BALLANTYNE ET AL.: "Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study", 《ATHEROSCLEROSIS》, vol. 277, pages 196 *
STEPHEN L. PINKOSKY ET AL.: "AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism", 《JOURNAL OF LIPID RESEARCH》, vol. 54, pages 134, XP055413416, DOI: 10.1194/jlr.M030528 *
陈霞: "低密度脂蛋白与糖尿病的关系", 《内科》, vol. 7, no. 3, pages 304 - 306 *

Also Published As

Publication number Publication date
SG11202101717WA (en) 2021-03-30
CO2021003726A2 (es) 2021-07-30
CL2021000444A1 (es) 2021-07-02
MX2021002090A (es) 2021-04-28
WO2020041799A1 (en) 2020-02-27
KR20210079275A (ko) 2021-06-29
BR112021003265A2 (pt) 2021-05-18
PH12021550656A1 (en) 2022-03-14
EP3841105A1 (en) 2021-06-30
JP2024081650A (ja) 2024-06-18
US20210322376A1 (en) 2021-10-21
IL281016A (en) 2021-04-29
JP2021534208A (ja) 2021-12-09
EP3841105A4 (en) 2022-05-04
AU2019325705A1 (en) 2021-03-18
CA3110346A1 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
CA3018132C (en) Use of elafibranor in the treatment of a cholestatic disease
CA2957466C (en) Drug combinations to treat multiple myeloma
BR112017016766B1 (pt) Composição compreendendo um agonista fxr e fibrato, bem como uso para tratar doença hepática colestática
JP6940411B2 (ja) Ｅｔｃ１００２及びエゼチミブを含む固定用量組合せ物及び製剤並びに心血管疾患を処置するか又は心血管疾患のリスクを低減させる方法
US12310935B2 (en) Methods of treatment of cholestatic diseases
JP2024081650A (ja) 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法
JP2022541503A (ja) Ｆｘｒアゴニストを使用した肝疾患の組み合わせ処置
EP3579827A1 (en) Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease
KR20190044666A (ko) Fxr 작용제들의 조합물
TW200306853A (en) Therapeutic agent for glomerular disease
TW202114654A (zh) 包含如sglt 1/2抑制劑的sglt抑制劑之治療
JP2021535136A (ja) 心血管疾患及び関連する状態を有する患者を処置するための併用薬製剤
WO2025168652A1 (en) Azd-0780 in combination with a statin for use in lowering ldl-c levels and treating cardiovacular diseases
KR20260042531A (ko) Pcsk9 억제제를 이용하여 콜레스테롤 관련 질환을 치료 또는 예방하기 위한 방법
HK40111798A (zh) 大麻素酸酯组合物及其用途
TW202604485A (zh) 患有肝損傷患者肝疾病之治療
HK40063789B (zh) 大麻素酸酯组合物及其用途
WO2021037702A1 (en) Pharmaceutical combination of a specific thienopyridone derivative with an fxr agonist for the treatment of liver diseases
CN101534825A (zh) 含有贝特类药物的制剂及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210723